Bronnen:
- Regan MM, Pagani O, Fleming GF, et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast. 2013;22:1094-100.,Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372:436-46.,Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014;371:107-18.,Gnant M, Mlineritsch B, Stoeger H, et al. Zoledrononic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group trial 12. Ann Oncol. 2015;26:313-20.,Francis PA, Pagani GF, Fleming BA, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122-37. Suppl. Francis PA, Pagani GF, Fleming BA, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379:122-37. Supplementary appendix.,Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient- level meta analysis of the randomized trials. Lancet. 2015;386:1341-52.,Bartlett JMS, Ahmed I, Regan MM, et al. HER2 status predicts for upfront AI benefit: a Trans-AIOG meta analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. Eur J Cancer. 2017;129-38.,IKNL. https://oncoline.nl/borstkanker 1.0; revisie 2017.,Francis PA, Pagani O, Regan MM. Reply to Letter to the editor of Patel A and Gupta GG. N Engl J Med. 2018;379:1683-5.